|
|
|
Overview: Immune globulin products from human plasma were first used in 1952 to treat immune deficiency. ... Uses of Intravenous Immunoglobulin...
|
emedicine.medscape.com/article/210367-overview
|
|
|
|
Medical treatment Intravenous immunoglobulin including conditions possibly treated or prevented by this treatment. ... Count: Intravenous immunoglobulin is listed as a: treatment for 13 conditions; alternative treatment for 0 conditions; preventive treatment for 0 conditions; research treatment for 1 conditions.
|
www.wrongdiagnosis.com/treat/intravenous_immunoglobulin...
www.wrongdiagnosis.com/treat/intravenous_immunoglobulin.htm
|
|
|
|
Use of intravenous immunoglobulin has increased the quality and length of many patients' lives. By making sure patients understand the risks and benefits, and by helping to minimize these risks, nurses play a key role in successful therapy. ... Intravenous immunoglobulin therapy: Some indications...
|
rn.modernmedicine.com/rnweb/article/articleDetail.jsp?i...
rn.modernmedicine.com/rnweb/article/articleDetail.jsp?id=482655
|
|
|
The present study was set up in order to evaluate the effectiveness of intravenous immunoglobulin (IVIG) treatment on the incidence of pneumonia in patients with agammaglobulinemia.
|
www.medscape.com/medline/abstract/14987729
|
|
Intravenous immunoglobulin (IVIg) is a concentrated solution of immunoglobulins (primarily gamma-globulin) prepared from the pooled plasma of human donors. ... Thrombotic Complications After Intravenous Immunoglobulin Therapy in Two Patients...
|
www.medscape.com/viewarticle/446805
|
|
Intravenous immunoglobulin (IVIG, also called intravenous gamma globlulin or IVGG) is a product derived from human blood that has been pooled from many donors. Plasma from approximately 1,000 to 10,000 persons is present in each unit or "lot" of IVIG.
|
www.hss.edu/conditions_14271.asp
|
|
Context Intravenous immunoglobulin (IVIG) enhances immune homeostasis by modulating expression and function of Fc receptors, interfering with activation of complement and production of cytokines, providing anti-idiotypic antibodies, and affecting the activation and effector functions of T and B cells.
|
jama.ama-assn.org/cgi/content/abstract/291/19/2367
|
|
BACKGROUND: Previous trials of intravenous immunoglobulin (IvIg) treatment of women with recurrent miscarriage (RM) have provided diverging results. This may be due to different inclusion criteria and suboptimal treatment protocols in some trials.
|
humrep.oxfordjournals.org/cgi/content/abstract/17/3/809
|
|